Department of Oncology, Skåne University Hospital, Lund, Sweden.
Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden.
BMC Cancer. 2022 Feb 9;22(1):157. doi: 10.1186/s12885-022-09253-5.
In childhood (CCS) and testicular cancer (TCS) survivors, low-grade inflammation may represent a link between testosterone deficiency (hypogonadism) and risk of metabolic syndrome. We aimed to study levels of inflammatory markers in CCS and TCS and the association with hypogonadism and future cardio-metabolic risk factors.
Serum levels of inflammatory markers and testosterone were analyzed in CCS (n = 90), and TCS (n = 64, median time from diagnosis: 20 and 2.0 years, respectively), and in controls (n = 44). Differences in levels between patients and controls were calculated using univariate analysis of variance. T-test and logistic regression were applied to compare levels of cardio-metabolic risk factors and odds ratio (OR) of hypogonadism and metabolic syndrome in low and high inflammatory marker groups after 4-12 years of follow up. Adjustment for age, smoking, and active cancer was made.
TCS and CCS, as compared to controls, had 1.44 (95%CI 1.06-1.96) and 1.25 (95 CI 1.02-1.53) times higher levels of IL-8, respectively. High IL-6 levels were associated with hypogonadism at baseline (OR 2.83, 95%CI 1.25-6.43) and the association was stronger for high IL-6 combined with low IL-10 levels (OR 3.10, 95%CI 1.37-7.01). High IL-6 levels were also associated with higher BMI, waist circumference, insulin, and HbA1c at follow up. High TNF-α was associated with higher diastolic blood pressure. No individual inflammatory marker was significantly associated with risk of metabolic syndrome at follow up. High IL-6 combined with low IL-10 levels were associated with risk of metabolic syndrome (OR 3.83, 95%CI 1.07-13.75), however not statistically significantly after adjustment.
TCS and CCS present with low-grade inflammation. High IL-6 levels were associated with hypogonadism and cardio-metabolic risk factors. Low IL-10 levels might reinforce the IL-6 mediated risk of developing metabolic syndrome.
在儿童期癌症（CCS）和睾丸癌（TCS）幸存者中，低度炎症可能是睾丸激素缺乏（性腺功能减退）与代谢综合征风险之间的联系。我们旨在研究 CCS 和 TCS 中炎症标志物的水平，以及与性腺功能减退和未来心血管代谢危险因素的关联。
分析了 90 例 CCS 患者（n=90）、64 例 TCS 患者（n=64，诊断后中位数时间分别为 20 年和 2.0 年）和 44 例对照组的血清炎症标志物和睾丸激素水平。使用单变量方差分析计算患者与对照组之间水平的差异。在 4-12 年的随访后，应用 t 检验和逻辑回归比较低和高炎症标志物组的心血管代谢危险因素水平和性腺功能减退及代谢综合征的比值比（OR）。进行了年龄、吸烟和活动性癌症的调整。
与对照组相比，TCS 和 CCS 的 IL-8 水平分别高 1.44（95%CI 1.06-1.96）和 1.25（95%CI 1.02-1.53）倍。高 IL-6 水平与基线时的性腺功能减退有关（OR 2.83，95%CI 1.25-6.43），而高 IL-6 结合低 IL-10 水平的关联更强（OR 3.10，95%CI 1.37-7.01）。高 IL-6 水平也与随访时的 BMI、腰围、胰岛素和 HbA1c 升高有关。高 TNF-α与舒张压升高有关。随访时，没有单独的炎症标志物与代谢综合征的风险显著相关。高 IL-6 结合低 IL-10 水平与代谢综合征的风险相关（OR 3.83，95%CI 1.07-13.75），但调整后无统计学意义。
TCS 和 CCS 表现为低度炎症。高 IL-6 水平与性腺功能减退和心血管代谢危险因素有关。低 IL-10 水平可能会加强 IL-6 介导的代谢综合征发病风险。
